Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen

Breast Cancer Research and Treatment

Volumn 68, Issue 2, 2001, Pages 101-110

  Scarpi, Emanuela ^a   De Paola, Franca ^a   Sarti, Manuela ^a   Bajorko, Paola ^a   Granato, Anna Maria ^a   Volpi, Annalisa ^b   Nanni, Oriana ^a   Maltoni, Roberta ^b   Amadori, Dino ^b  

^a ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

Author keywords

Biomarkers; N+ ER+ breast cancer; Predictivity; Tamoxifen

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P27; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE C ERB; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPH NODES; MICROFILAMENT PROTEINS; MIDDLE AGED; MUSCLE PROTEINS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TAMOXIFEN; THYMIDINE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0034793420     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011975510181     Document Type: Article

References (48)

1. Cancer incidence in five continents
2. Prognostic factors in breast cancer
3. Breast cancer metastasis-associated genes: Prognostic significance and therapeutic implications
4. Commentary: Meeting highlights - International Consensus Panel on the Treatment of Primary Breast Cancer
5. Critical evaluation of prognostic factor
6. ERBB2 oncogene in human breast cancer and its clinical significance
7. Use of HER2 for predicting response to breast cancer therapy
8. C-erbB-2, p53 protein expression and steroid hormone receptor in breast carcinomas: An immunohistochemical study
9. Bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group Study
10. kip1 and apoptosis in human breast cancer
11. kip1
12. Prognostic and predictive factors
13. Estrogen receptor negative and progesterone receptor positive primary breast cancer: Pathological characteristics and clinical outcome
14. Tamoxifen for early breast cancer: An overview of the randomised trials
15. Steroid hormone receptor in breast cancer management
16. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer
17. Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy
18. Relationship of variations in tumor cell kinetics induced by primary chemotherapy to tumor regression and prognosis in locally advanced breast cancer
19. Tumor proliferative activity and response to first-line chemotherapy in advanced breast carcinoma
20. Primary chemotherapy in breast invasive carcinoma: Predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi
21. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas
22. C-erbB-2 expression predicts response to preoperative chemotherapy for locally advanced breast cancer
23. S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer
24. Recurrence-free survival in breast cancer improved by adjuvant tamoxifen-especially for progesterone receptor positive tumors with a high proliferation
25. A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer
26. Quantitative determination of c-erbB-2 in human breast tumours: Potential prognostic significance of low values
27. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
28. 1a, b) invasive breast carcinomas
29. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients
30. kip1 protein: Prognostic implications in primary breast cancer
31. Cell cycle proteins do not predict outcome in grade I infiltrating ductal carcinoma of the breast
32. Elevated levels of p27, p21 and cyclin D1 correlate with positive oestrogen and progesterone receptor status in node-negative breast carcinoma patients
33. Prognostic significance of biologic markers in node-negative breast cancer patients: A prospective study
34. 3H-TdR Labeling Index in breast cancer
35. Characterization of laboratory working standards for quality control of immunometric and radiometric estrogen receptor assays. Clinical evaluation of breast cancer biopsies
36. Non parametric estimation for incomplete observation
37. Is the negative prognostic value of high oestrogen receptor (ER) levels in postmenopausal breast cancer patients due to a modified ER gene product?
38. Short recurrence-free survival associated with high oestrogen receptor levels in the natural history of postmenopausal, primary breast cancer
39. HER-2/neu in node-positive breast cancer: Prognostic significance of overexpression influenced by the presence of in situ carcinoma
40. DFS advantage of adjuvant CMF in node negative rapidly proliferating breast cancer patients: A randomised multicentre study
41. Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer
42. Regression models and life tables
43. Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers
44. Classical prognostic factors for survival and loco-regional control in breast cancer patients treated with radical mastectomy alone
45. Clinical relevance of cell kinetics in breast cancer
46. Tumor proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor positive advanced breast cancer